Uniqure NV - Asset Resilience Ratio
Uniqure NV (QURE) has an Asset Resilience Ratio of 10.94% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Uniqure NV's Asset Resilience Ratio has changed over time. Check Uniqure NV (QURE) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Uniqure NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Uniqure NV.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $97.19 Million | 10.94% |
| Total Liquid Assets | $97.19 Million | 10.94% |
Asset Resilience Insights
- Moderate Liquidity: Uniqure NV has 10.94% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Uniqure NV Industry Peers by Asset Resilience Ratio
Compare Uniqure NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Uniqure NV (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Uniqure NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 37.48% | $208.59 Million | $556.54 Million | -7.79pp |
| 2023-12-31 | 45.27% | $376.53 Million | $831.69 Million | +27.57pp |
| 2022-12-31 | 17.71% | $124.83 Million | $704.96 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $809.18 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $208.88 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $190.26 Million | -- |
About Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more